Browsing SIHF Open Archive by Author "Deyab, Gia"
Now showing items 1-3 of 3
-
Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
Deyab, Gia; Hokstad, Ingrid; Whist, Jon Elling; Småstuen, Milada Cvancarova; Agewall, Stefan; Lyberg, Torstein; Bottazzi, Barbara; Meroni, Pier Luigi; Leone, Roberto; Hjeltnes, Gunnbjørg; Hollan, Ivana (Peer reviewed; Journal article, 2017)Background Pentraxin 3 is proposed to be a marker of inflammation and cardiovascular risk, but its role in inflammatory rheumatic diseases (IRDs) is still uncertain. Therefore, we wanted to examine if anti-rheumatic ... -
Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis
Deyab, Gia; Hokstad, Ingrid; Whist, Jon Elling; Småstuen, Milada C; Agewall, Stefan; Lyberg, Torstein; Ronda, Nicoletta; Mikkelsen, Knut; Hjeltnes, Gunnbjørg; Hollan, Ivana (Journal article; Peer reviewed, 2017)Background Inflammatory arthritis (IA), including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA), leads to increased cardiovascular disease occurrence probably due to atherosclerosis. ... -
Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: An observational study
Hokstad, Ingrid; Deyab, Gia; Fagerland, Morten; Lyberg, Torstein; Hjeltnes, Gunnbjørg; Førre, Øystein Thorleiv; Agewall, Stefan; Mollnes, Tom Eirik; Hollan, Ivana (Journal article; Peer reviewed, 2019)Background The complement system is involved in pathogenesis of cardiovascular disease, and might play a role in accelerated atherogenesis in spondylarthropathies (SpA). Hence, we examined complement activation in SpA, and ...